Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-B99 in first-line extensive-stage small cell lung cancer
2020-005649-17Phase 2Active
- Sponsor
- Merck & Co.
- Start
- Apr 2021
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of pembrolizumab, lenvatinib, mk-4830, omaveloxolone, etoposide and 2 more in small cell lung cancer (SCLC) (3 arms), sponsored by Merck & Co. Primary endpoint: Objective Response Rate. Started Apr 2021; status: active.
02
Drugs
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on 2020-005649-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005649-17.